145 related articles for article (PubMed ID: 8089867)
1. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma.
Uhlman DL; Nguyen PL; Manivel JC; Aeppli D; Resnick JM; Fraley EE; Zhang G; Niehans GA
J Natl Cancer Inst; 1994 Oct; 86(19):1470-5. PubMed ID: 8089867
[TBL] [Abstract][Full Text] [Related]
2. P53 mutations and other prognostic factors of renal cell carcinoma.
Girgin C; Tarhan H; Hekimgil M; Sezer A; Gürel G
Urol Int; 2001; 66(2):78-83. PubMed ID: 11223748
[TBL] [Abstract][Full Text] [Related]
3. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
4. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma.
Rioux-Leclercq N; Turlin B; Bansard J; Patard J; Manunta A; Moulinoux JP; Guillé F; Ramée MP; Lobel B
Urology; 2000 Apr; 55(4):501-5. PubMed ID: 10736491
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
6. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
Navone NM; Troncoso P; Pisters LL; Goodrow TL; Palmer JL; Nichols WW; von Eschenbach AC; Conti CJ
J Natl Cancer Inst; 1993 Oct; 85(20):1657-69. PubMed ID: 7692074
[TBL] [Abstract][Full Text] [Related]
7. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors.
Lee CT; Genega EM; Hutchinson B; Fearn PA; Kattan MW; Russo P; Reuter VE
Urol Oncol; 2003; 21(3):179-84. PubMed ID: 12810203
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis.
Uhlman DL; Nguyen P; Manivel JC; Zhang G; Hagen K; Fraley E; Aeppli D; Niehans GA
Clin Cancer Res; 1995 Aug; 1(8):913-20. PubMed ID: 9816062
[TBL] [Abstract][Full Text] [Related]
11. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome.
Horiguchi A; Oya M; Shimada T; Uchida A; Marumo K; Murai M
J Urol; 2002 Aug; 168(2):762-5. PubMed ID: 12131365
[TBL] [Abstract][Full Text] [Related]
12. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
[TBL] [Abstract][Full Text] [Related]
13. Incidence of apoptosis, cell proliferation and P53 expression in renal cell carcinomas.
Tannapfel A; Hahn HA; Katalinic A; Fietkau RJ; Kühn R; Wittekind CW
Anticancer Res; 1997; 17(2A):1155-62. PubMed ID: 9137464
[TBL] [Abstract][Full Text] [Related]
14. Detection of p53 gene alteration in renal-cell cancer by micropreparation techniques of tumor specimens.
Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Arndt H; Paeslack U; Werner M; Tan HK; Jonas U
Int J Cancer; 1995 Dec; 64(6):399-406. PubMed ID: 8550242
[TBL] [Abstract][Full Text] [Related]
15. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
17. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma.
da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S
Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457
[TBL] [Abstract][Full Text] [Related]
18. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
[TBL] [Abstract][Full Text] [Related]
19. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 9 and 17 aberrations and p53 gene deletion detected by fluorescence in situ hybridization in renal-cell carcinoma.
Yoshioka K; Nakamura S
Mol Urol; 2001; 5(1):11-7. PubMed ID: 11689146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
